Meeting
2023 ASCO Annual Meeting
Randomized double-blind, placebo-controlled study of topical diclofenac in prevention of hand-foot syndrome in patients receiving capecitabine.
Presenter
Atul Batra, MD, DM
Dr. Brairch, All India Institute of Medical Sciences
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
CTRI/2021/01/030592
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 12005)
DOI
10.1200/JCO.2023.41.16_suppl.12005
Abstract #
12005
Abstract Disclosures
Similar Videos & Slides
Speaker: Panel Discussion
Videos & Slides
2022 ASCO Genitourinary Cancers Symposium
Part 1 results from NOVA-II, a randomized, double-blind, vehicle-controlled phase II study evaluating the safety and efficacy of OQL011 on VEGFR inhibitor associated hand-foot skin reaction in cancer patients.
Speaker: Mario E. Lacouture, MD
Speaker: Ann H. Partridge, MD, MPH, FASCO
Videos & Slides
2018 Gastrointestinal Cancers Symposium
RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma.
Speaker: Charles S. Fuchs, MD